Nonlinear pharmacokinetics of fluvoxamine and gender differences

Therapeutic Drug Monitoring

Volumn 20, Issue 4, 1998, Pages 446-449

  Härtter, Sebastian ^a   Wetzel, Herman ^b   Hammes, Elke ^b   Torkzadeh, Massud ^b   Hiemke, Christoph ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

Fluvoxamine; Gender differences; Pharmacokinetics; Selective serotonin reuptake inhibitors

Indexed keywords

FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENDER; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 0344404402     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199808000-00016     Document Type: Article

References (19)

1. De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43(suppl 2):40-7.
2. De Vries MH, Raghoebar M, Mathlener, IS, van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992;14:493-8.
3. De Vries MH, Van Harten J, Van Bemmel P, Raghoebar M. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos 1993;14:291-6.
4. De Wilde JEM, Doogan P. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982;4:249-59.
5. Klok CJ, Brouwer GJ, Van Praag HM, Doogan D. Fluvoxamine and clomipramine in depressed patients: a double-blind clinical study. Acta Psychiatr Scand 1981;64:1-11.
6. Kasper S, Dötsch M, Kick H, Vieira A, Möller H-J. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on the therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993;3:13-21.
7. Spigset O, Gramberg K, Hägg S, Söderström E, Carleborg L, Dahlqvist R. Nonlinear fluvoxamine disposition and relation to some CYP activities. Eur J Clin Pharmacol 1997;52(suppl):A172.
8. Van Harten J. Overview of the pharmacokientics of fluvoxamine. Clin Pharmacokinet 1995;29(suppl 1):1-9.
9. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association. 1987.
10. Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatopgraphy. Clin Chem 1992;38:2082-6.
11. Rowland M, Tozer TN, eds. Clinical Pharmacokinetics: Concepts and Applications. 2nd ed. Philadelphia: Lea & Febiger; 1989.
12. De Bree H, Van der School JB, Post LC. Fluvoxamine maleate: disposition in man. Eur J Drug Metab Pharmacokinet 1983;8:170-175.
13. Brøsen K, Gram LF, Klysner R, Bech P. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986;30:43-9.
14. Cooke RG, Warsh JJ, Stancer HC, Reed KL, Persad E. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clin Pharmacol Ther 1984;36:343-8.
15. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlineraity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
16. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.
17. Carrillo JA, Dahl ML, Svensson J-O, Engr CA, Inmaculada R, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphicc CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
18. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
19. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-39.